NCT02964910View on ClinicalTrials.gov

A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )

PHASE4CompletedINTERVENTIONAL

Enrollment

475

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

December 31, 2017

Conditions

Hepatitis E

Interventions

BIOLOGICAL

Recombinant Hepatitis E Vaccine (Escherichia Coli)

Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.

Trial Locations (1)

Unknown

Rushan Center for Disease Control and Prevention, Weihai

All Listed Sponsors

lead

Xiamen Innovax Biotech Co., Ltd

INDUSTRY

NCT02964910 - A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients ) | Biotech Hunter | Biotech Hunter